Synonym
Eprozinol Free Base; Eprozinolum; Eupneron; EINECS 251-146-9
IUPAC/Chemical Name
1-Piperazinepropanol, 4-(2-methoxy-2-phenylethyl)-alpha-phenyl- (9CI)
InChi Key
QSRHLIUOSXVKTG-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H30N2O2/c1-26-22(20-10-6-3-7-11-20)18-24-16-14-23(15-17-24)13-12-21(25)19-8-4-2-5-9-19/h2-11,21-22,25H,12-18H2,1H3
SMILES Code
OC(C1=CC=CC=C1)CCN2CCN(CC(OC)C3=CC=CC=C3)CC2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
354.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Labrid C, Dureng G, Duchene-Marullaz P, Moleyre J. Dualist or pseudo-dualist interactions of mepyramine, diphenhydramine and eprozinol with histamine at H1-receptors. Jpn J Pharmacol. 1977 Aug;27(4):491-500. doi: 10.1254/jjp.27.491. PMID: 21982.
2: Labrid C, Burtin C, Stoclet JC, Dureng G, Schoeffter P, Lebel B, Duchene- Marullaz P. Mechanisms of anti-bronchoconstrictive effects of eprozinol. I. In vitro studies. Pharmacology. 1981;23(1):31-47. doi: 10.1159/000137525. PMID: 6171839.
3: Nicrosini F, Carpinella G. Traitement par l'eprozinol des bronchites chroniques s'accompagnant de dyspnée et de toux [Eprozinol treatment of chronic bronchitis with dyspnea and cough]. Bronchopneumologie. 1978 Jul- Aug;28(4):322-7. French. PMID: 756799.
4: Labrid C, Duchene-Marullaz P, Rispat G. Mechanisms of anti- bronchoconstrictive effects of eprozinol. II. In vivo studies on the guinea pig. Pharmacology. 1981;23(1):48-55. doi: 10.1159/000137526. PMID: 7312935.
5: Merigot P, Garnier R, Efthymiou ML. Les convulsions avec trois antitussifs dérivés substitués de la pipérazine (zipéprol, éprazinone, éprozinol) [Convulsions with 3 antitussive substituted derivatives of piperazine (zipeprol, eprazinone, eprozinol)]. Ann Pediatr (Paris). 1985 Jun;32(6):504-6, 511. French. PMID: 4026148.
6: Duchene-Marullaz P, Rispat G, Perriere JP. De quelques aspects pharmacodynamiques anti-histaminiques, notamment de l'Eprozinol [Several antihistaminic pharmacodynamic aspects, especially of Eprozinol]. Therapie. 1971 Jan-Feb;26(1):155-62. French. PMID: 4396627.
7: Sors C, Dutartre D. Etude clinique d'un nouvel antispasmodique bronchique, l'Eprozinol [Clinical study of a new bronchial antispasmodic, epronizol]. Therapie. 1971 Jan-Feb;26(1):163-71. French. PMID: 5554762.
